Gwen Stefani Headlined the 19th Annual Feinstein Summer Concert | Raises $3.6M to Support Medical Innovation

Grammy Award-winning, multiplatinum-selling global singer-songwriter Gwen Stefani headlined the 19th annual Feinstein Summer Concert, which raised $3.6 million to advance scientific discovery at Northwell Health’s Feinstein Institutes for Medical Research.

For more than two decades, researchers at the Feinstein Institutes have made important discoveries that have transformed the treatment of conditions such as lupus, arthritis, sepsis, cancer, psychiatric illnesses and Alzheimer’s disease. More than 5,000 researchers and staff at the Feinstein Institutes are dedicated to producing knowledge to cure disease, directly impacting the care of over 2 million Northwell patients each year.

“The remarkable work at the Feinstein Institutes sets it apart as a global leader that is truly changing the future of how we treat disease,” said Northwell President and CEO Michael J. Dowling. “Thanks to our generous donors and the collaborative nature within Northwell, we are able to push boundaries in meaningful ways to improve health care for all.”

Since its inception, the Feinstein Summer Concert has raised more than $40 million to accelerate research and fuel the development of innovative therapies to treat illness and cure disease. The event, held on July 11th at Old Westbury Gardens, propels Northwell’s ability to pioneer solutions that are impacting the trajectory of medicine around the world.

“For 19 years, the Feinstein Summer Concert has fostered an extraordinary community of supporters who champion our mission to discover and invent groundbreaking therapeutic innovations,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research. “Philanthropy has a remarkable ripple effect; each supporter and advocate starts a ripple that makes a lasting impact on future health care, locally and worldwide. Our generous donors enable Northwell to alleviate suffering and illness by making medical breakthroughs and leading clinical trials aimed at curing and eradicating disease.”

Chris Wragge, co-anchor of “CBS 2 News This Morning” and “CBS 2 News at Noon,” served as the event’s emcee for the eighth year. Catering and event design were coordinated by Larry Scott of Lawrence Scott Events. The Feinstein Institutes thanks its generous donors and this year’s leadership sponsors, the Susan and Leonard Feinstein Foundation and Donald Zucker and Barbara Hrbek Zucker.

The Feinstein Summer Concert supports Northwell’s Outpacing the Impossible campaign, a comprehensive $1.4 billion fundraising effort that supports Northwell’s promise to the people it serves. The campaign’s objectives include improving hospitals and clinical programs, accelerating research and funding endowment.

For more information about supporting the Feinstein Institutes and Northwell Health, visit: give.northwell.edu/feinstein-institutes-medical-research.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”